Claims
- 1. A liposomal composition comprising at least one liposome that comprises at least one monolipopeptide and at least one dilipopeptide.
- 2. The liposomal composition according to claim 1, wherein said monolipopeptide and said dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 3. The liposomal composition according to claim 1, wherein the monolipopeptide and the dilipopeptide have different amino acid sequences.
- 4. The liposomal composition of claim 1, wherein the percentage of said monolipopeptide varies from more than 0 to less than about 100%, and wherein the percentage of said dilipopeptide varies from more than 0 to less than about 100%, based on the total lipopeptides incorporated in said liposome.
- 5. The liposomal composition of claim 4, wherein the percentage of said monolipopeptide and the percentage of said dilipopeptide incorporated in said liposome are each about 50%.
- 6. The liposomal composition of claim 4, wherein the percentage of said monolipopeptide is from about 50 to about 99%
- 7. The liposomal composition of claim 4, wherein the percentage of said dilipopeptide is from about 50 to about 99%.
- 8. The liposomal composition of claim 1, wherein the monolipopeptide and the dilipopeptide are different antigenic epitopes.
- 9. The liposomal composition of claim 8, wherein the antigenic epitopes are from different proteins.
- 10. The liposomal composition according to claim 1, wherein said monolipopeptide and said dilipopeptide peptide are any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 11. A liposomal formulation comprising a first liposomal composition and a second liposomal composition, wherein the first liposomal composition comprises a monolipopeptide and wherein the second liposomal composition comprises a dilipopeptide.
- 12. The liposomal formulation according to claim 11, wherein the monolipopeptide and the dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 13. The liposomal formulation according to claim 11, wherein said monolipopeptide and the dilipopeptide peptide is any sequence, in whole or in part, selected from any one of SEQ ID NOs.1-4.
- 14. The liposomal formulation according to claim 11, wherein the monolipopeptide and the dilipopeptide have different amino acid sequences.
- 15. The liposomal formulation according to claim 11, wherein the monolipopeptide and the dilipopeptide have the same amino acid sequence.
- 16. A method for modulating an immune response comprising administering to a patient an effective amount of at least one monolipopeptide and at least one dilipopeptide.
- 17. The method of claim 16, wherein said monolipopeptide and said dilipopeptide are incorporated into a liposome, wherein the percentage of said monolipopeptide varies from more than 0 to less than about 100%, and wherein the percentage of said dilipopeptide varies from more than 0 to less than about 100%, based upon the total lipopeptides incorporated in said liposome.
- 18. The method of claim 17, wherein the percentage of said monolipopeptide and the percentage of said dilipopeptide incorporated in said liposome are each about 50%.
- 19. The method of claim 17, wherein the percentage of said monolipopeptide is from about 50 to about 99%
- 20. The method of claim 17, wherein the percentage of said dilipopeptide is from about 50 to about 99%.
- 21. The method of claim 16, wherein the modulation results in the stimulation of a humoral response.
- 22. The method of claim 16, wherein the modulation results in the stimulation of a cellular response.
- 23. The method of claim 16, wherein the modulation results in an increase in the intensity of at least one of a humoral response or a cellular response.
- 24. The method of claim 16, wherein said monolipopeptide and said dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 25. The method of claim 16, wherein said monolipopeptide and said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 26. The method of claim 16 further comprising co-administering an adjuvant with said monolipopeptide and said dilipopeptide.
- 27. The method of claim 26, wherein said adjuvant is lipid A.
- 28. A method of modulating an immune response, comprising simultaneously administering a formulation comprising a liposomally-bound monolipopeptide and a formulation comprising a liposomally-bound dilipopeptide.
- 29. The method of claim 28, wherein said monolipopeptide and said dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 30. The method of claim 28, wherein said monolipopeptide and said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.14.
- 31. The method of claim 28, wherein said monolipopeptide and said dilipopeptide have the same amino acid sequence.
- 32. A method of modulating between a cellular and humoral immune response, comprising first administering a formulation comprising a liposomally-bound monolipopeptide and then subsequently administering a formulation comprising a liposomally-bound dilipopeptide.
- 33. The method of claim 32, wherein said monolipopeptide and said dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 34. The method of claim 32, wherein said monolipopeptide and said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 35. The method of claim 32, wherein said monolipopeptide and said dilipopeptide have the same amino acid sequence.
- 36. A method of modulating between a cellular and humoral immune response, comprising first administering a formulation comprising a liposomally-bound dilipopeptide and then subsequently administering a formulation comprising a liposomally-bound monolipopeptide.
- 37. The method of claim 36, wherein said monolipopeptide and said dilipopeptide are selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 38. The method of claim 36, wherein said monolipopeptide and said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 39. The method of claim 36, wherein said monolipopeptide and said dilipopeptide have the same amino acid sequence.
- 40. A method for modulating an immune response comprising administering to an individual at least one liposome which consists essentially of a dilipopeptide.
- 41. The method according to claim 40, wherein said dilipopeptide is selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 42. The method of claim 40, wherein said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 43. A method for modulating an immune response comprising administering to an individual at least one liposome which consists of a dilipopeptide.
- 44. The method according to claim 43, wherein said dilipopeptide is selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 45. The method of claim 43, wherein said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 46. A method for modulating an immune response comprising administering to an individual at least one liposome which comprises a dilipopeptide.
- 47. The method according to claim 46, wherein said dilipopeptide is selected from the group consisting of MUC I, tuberculosis, malaria, and hepatitis B peptides.
- 48. The method of claim 46, wherein said dilipopeptide peptide is any sequence, in whole or in part, selected from SEQ ID NOs.1-4.
- 49. A MUC I peptide composition comprising one lipid attached to an amino acid of the MUC I peptide.
- 50. The MUC I peptide composition according to claim 49, comprising in whole or in part the sequence of SEQ ID NO. 1.
- 51. The MUC I peptide composition of claim 49, comprising the sequence SGVTSAPDTRPAPGSTA or STAPPAHGVTSAPDTRPAPGSTAPP.
- 52. A MUC I peptide composition according to claim 49 further comprising a second lipid attached to an amino acid of the MUC I peptide.
- 53. The MUC I peptide composition according to claim 52, comprising in whole or in part the sequence of SEQ ID NO. 1.
- 54. The MUC I peptide composition of claim 52, comprising the sequence SGVTSAPDTRPAPGSTA or STAPPAHGVTSAPDTRPAPGSTAPP.
- 55. A MUC I peptide composition according to claim 52, wherein each lipid is attached to different amino acids.
- 56. A MUC I peptide composition according to claim 52 wherein the lipids are positioned at either the N-terminus or the C-terminus of the MUC I peptide.
- 57. A tuberculosis peptide composition comprising one lipid attached to an amino acid of the tuberculosis peptide.
- 58. The tuberculosis peptide composition of claim 55, comprising the sequence DQVHFQPLPPAVVKLSDALIK.
- 59. A tuberculosis peptide composition comprising two lipids attached to at least one amino acid of the tuberculosis peptide.
- 60. The tuberculosis peptide composition of claim 59, comprising the sequence DQVHFQPLPPAVVKLSDALIK.
- 61. A tuberculosis peptide composition according to claim 59, wherein each lipid is attached to different amino acids.
- 62. A tuberculosis peptide composition according to claim 59, wherein the lipids are positioned at either the N-terminus or the C-terminus of the tuberculosis peptide.
- 63. A hepatitis B peptide composition comprising one lipid attached to an amino acid of the hepatitis B peptide.
- 64. The hepatitis B peptide composition of claim 63 comprising the sequence IRTPPAYRPPNAPILK.
- 65. A hepatitis B peptide composition comprising two lipids attached to at least one amino acid of the hepatitis B peptide.
- 66. The hepatitis B peptide composition of claim 65, comprising the sequence IRTPPAYRPPNAPILK.
- 67. A hepatitis B peptide composition according to claim 65, wherein each lipid is attached to different amino acids.
- 68. A hepatitis B peptide composition according to claim 65, wherein the lipids are positioned at either the N-terminus or the C-terminus of the hepatitis B peptide.
- 69. A malaria peptide composition comprising one lipid attached to an amino acid of the malaria peptide.
- 70. The malaria peptide composition of claim 69, comprising the sequence VTHESYQELVKKLEALEDAVK.
- 71. A malaria peptide composition comprising two lipids attached to at least one amino acid of the malaria peptide.
- 72. The malaria peptide composition of claim 71, comprising the sequence VTHESYQELVKKLEALEDAVK.
- 73. A malaria peptide composition according to claim 71, wherein each lipid is attached to different amino acids.
- 74. A malaria peptide composition according to claim 71, wherein the lipids are positioned at either the N-terminus or the C-terminus of the malaria peptide.
- 75. A peptide selected from the group consisting of SEQ ID NOs 1-4, comprising more than two lipids.
- 76. A MUC I peptide composition according to any one of claims 49 or 52, wherein the lipid(s) is selected from the group consisting of myristyl, palmitoyl and lauryl.
- 77. A tuberculosis peptide composition according to any one of claims 57 or 59, wherein the lipid(s) is selected from the group consisting of myristyl, palmitoyl and lauryl.
- 78. A hepatitis B peptide composition according to any one of claims 63 or 65, wherein the lipid(s) is selected from the group consisting of myristyl, palmitoyl and lauryl.
- 79. A malaria peptide composition according to any one of claims 69 or 71, wherein the lipid(s) is selected from the group consisting of myristyl, palmitoyl and lauryl.
- 80. The method of any one of claims 28, 32, 36, 40, 43 or 46, further comprising co-administering an adjuvant.
- 81. The method of claim 80, wherein said adjuvant is lipid A.
Parent Case Info
[0001] This application claims priority to U.S. provisional application No. 60/278,698 entitled “Vaccine For Modulating Between T1 And T2 Immune Responses,” filed on Mar. 27, 2001, which is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60278698 |
Mar 2001 |
US |